MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

IBUPROFEN; METHOCARBAMOL

제공처:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATC 코드:

M03BA53

INN (International Name):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

복용량:

200MG; 500MG

약제 형태:

TABLET

구성:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

OTC

치료 영역:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

제품 요약:

Active ingredient group (AIG) number: 0248961001; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2017-06-13

제품 특성 요약

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............